Understanding, recognizing, and managing toxicities of targeted anticancer therapies.
about
Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingTreatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancerDiscoidin Domain Receptors: Potential Actors and Targets in CancerAdvancing a comprehensive cancer care agenda for children and their families: Institute of Medicine Workshop highlights and next stepsManagement of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistanceMolecular targeted approaches to cancer therapy and prevention using chalconesTargeted therapies in development for non-small cell lung cancerStructure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodiesLatest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapiesCardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational studyEpidermal RAF prevents allergic skin diseaseRRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.A new sensitizer DVDMS combined with multiple focused ultrasound treatments: an effective antitumor strategy.2-Arachidonoylglycerol enhances platelet formation from human megakaryoblasts.Translational Modeling of Drug-Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor.Tumor angiogenesis therapy using targeted delivery of Paclitaxel to the vasculature of breast cancer metastases.Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practiceToward a Cancer Drug of Fungal OriginRecognition and Management of Oral Mucosal Injury Caused by Mammalian Target of Rapamycin Inhibitors: A Case SeriesInhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice.Targeting prion-like protein doppel selectively suppresses tumor angiogenesis.Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signallingA recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.The role of active brown adipose tissue (aBAT) in lipid metabolism in healthy Chinese adults.Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking.Treatment with an SLC12A1 antagonist inhibits tumorigenesis in a subset of hepatocellular carcinomas.Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy.The application of mRNA-based gene transfer in mesenchymal stem cell-mediated cytotoxicity of glioma cells.Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.Oral mucosal injury caused by cancer therapies: current management and new frontiers in research.Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors.Phase 1 trial design: is 3 + 3 the best?Side effects of cytokines approved for therapy.The changing landscape of phase I trials in oncology.Porphyrin-loaded nanoparticles for cancer theranostics.Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer.SM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis.Adipose‑derived mesenchymal stem cell‑facilitated TRAIL expression in melanoma treatment in vitro.Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer.
P2860
Q23923997-3E7A6803-C80B-484F-B21D-743969CDF2DFQ26747335-A4B0A19D-350F-4A73-A7D5-E233AE3A4ADBQ26751157-1F6214AC-7162-4193-A76A-74BA4F6AB96DQ26752816-16400A98-027D-4904-8D75-EE94ED6EC3FEQ26775379-C5596707-BC8C-4C7C-9F0A-75AA8E59B0F7Q27021479-2CB92CE5-D491-4DBE-856C-620149B5E43EQ27022852-2E14E3FB-EAC9-4995-AA0B-489DA4C14F1CQ27681380-4D6BBD1E-DD39-4679-B1C4-FBFE3137883AQ28395597-79A63E00-3E83-492B-A82C-1FA09EA2A076Q28545130-422F7CB0-ED70-4EE8-8A49-3C6B08658301Q28829587-986037B6-A92D-4B51-A356-4854F2503B63Q30010522-E7E917BB-8392-49B2-A14A-1765268F785AQ30396581-02D2F92A-1E78-4654-8413-E0AFBBF868AAQ33418879-B19988B4-C653-4011-94CD-2283B97DCE4EQ33440695-381EB60B-A03C-4683-AFCF-868B9D05FDCBQ34755104-80520E62-C466-481D-A76E-DF5453D4FB30Q35200569-7F8A6AD9-3EDB-4875-95CC-D7FBE8E832C1Q35596957-B82B5D72-3A71-45CC-9966-FE1D22DC6196Q36118205-C17F5FDB-1A4A-454F-9237-DC350C346347Q36548326-B6D90BC6-A79F-4040-9CEE-B9FA536BA56BQ36737935-8B3C2285-8A69-4BF0-A199-D5D365042B3DQ36892992-B011493A-2074-4DB1-9CA2-D259B259E6B4Q37052843-F1D77089-69DF-4484-89BB-FC6B6BDFF184Q37209641-B26045FB-B5A9-4716-9666-1E16DF94E8D5Q37353724-A1555EE7-7C6C-4F65-8F61-975DD1923FB3Q37397983-A73B68C6-B8DE-42C4-B412-4D9CF884B51AQ37619791-17F34DDF-B79F-4A1E-B034-4B525DF98AACQ37677564-D7D4D3C8-EE18-432A-BF6C-3153DFF1000AQ37688267-27D819F5-11BE-4A33-A078-56D6C4D6532BQ37723370-787FF354-5E44-4AAA-A8F9-BBF86989CEF3Q38164809-18D4C31B-DC6C-46A0-8233-4540DA1F0866Q38207484-07FB5AE4-7E74-4234-9985-2FA0F5AA318EQ38222466-F4C9D4D1-9659-458E-B452-EB4BC1B8C1E4Q38255698-69AAD723-0304-4DC4-AF91-49D4DBA1934FQ38629203-0885C6EF-A8AD-431B-9572-ECEE61D37C69Q38686870-3FEAA604-0E22-42FD-8D59-AFB599E3B40BQ38728508-2446389A-4BC4-4AD8-AA4A-F06B548C6107Q38753997-734D96FA-97DF-4DF8-8DC2-A38A0284C5CAQ38771132-914C4E5F-5EA8-49BB-ABB5-4B7F5015162EQ38786021-8D25926D-D921-4336-862A-C679C0DDFA22
P2860
Understanding, recognizing, and managing toxicities of targeted anticancer therapies.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Understanding, recognizing, and managing toxicities of targeted anticancer therapies.
@ast
Understanding, recognizing, and managing toxicities of targeted anticancer therapies.
@en
type
label
Understanding, recognizing, and managing toxicities of targeted anticancer therapies.
@ast
Understanding, recognizing, and managing toxicities of targeted anticancer therapies.
@en
prefLabel
Understanding, recognizing, and managing toxicities of targeted anticancer therapies.
@ast
Understanding, recognizing, and managing toxicities of targeted anticancer therapies.
@en
P2860
P356
P1433
P1476
Understanding, recognizing, and managing toxicities of targeted anticancer therapies.
@en
P2093
Alex A Adjei
Grace K Dy
P2860
P304
P356
10.3322/CAAC.21184
P407
P577
2013-05-28T00:00:00Z